Faron Pharmaceuticals
1.728
EUR
+2.73 %
FARON
First North Finland
Biotechnology & Pharmaceuticals
Health Care
Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.
Read moreLatest research
Extensive report
Analyst
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Citibank Europe PLC | 25.8 % | 25.8 % |
Skandinaviska Enskilda Banken AB | 7.0 % | 7.0 % |
Premium
This content is for our Premium customers only.
Forum updates
Income statement
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.4 |
growth-% | 86,030.6 % | |||||||
EBITDA | -16.4 | -20.8 | -27.4 | -28.2 | -25.7 | -29.0 | -30.3 | -27.6 |
EBIT (adj.) | -16.7 | -21.1 | -27.4 | -28.6 | -26.1 | -29.2 | -30.5 | -27.8 |
EBIT | -16.7 | -21.1 | -27.4 | -28.6 | -26.1 | -29.2 | -30.5 | -27.8 |
Profit before taxes | -16.9 | -21.2 | -28.7 | -30.9 | -29.7 | -31.2 | -32.7 | -30.2 |
Net income | -16.9 | -21.2 | -28.6 | -30.9 | -29.7 | -31.2 | -32.7 | -30.2 |
EPS (adj.) | -0.36 | -0.40 | -0.48 | -0.45 | -0.28 | -0.30 | -0.31 | -0.29 |
growth-% | ||||||||
Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Dividend ratio |
Login required
This content is only available for logged in users
Profitability and return on capital
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
EBITDA-% | -409,275.0 % | -520,050.0 % | -685,675.0 % | -705,550.0 % | -643,250.0 % | -725,782.5 % | -758,350.0 % | -801.6 % |
EBIT-% (adj.) | -416,350.0 % | -527,700.0 % | -685,650.0 % | -714,200.0 % | -653,250.0 % | -730,500.0 % | -762,390.0 % | -805.6 % |
EBIT-% | -416,350.0 % | -527,700.0 % | -685,650.0 % | -714,200.0 % | -653,250.0 % | -730,500.0 % | -762,390.0 % | -805.6 % |
ROE | 14,063.1 % | -3,920.3 % | 670.4 % | 232.3 % | 234.3 % | 120.9 % | 56.6 % | 33.8 % |
ROI | -676.3 % | -588.9 % | -707.3 % | 7,250.8 % | 3,960.6 % | -3,336.9 % | -4,042.5 % | -4,212.1 % |
Login required
This content is only available for logged in users
Valuation
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Share price (EUR) | 2.91 | 3.24 | 3.71 | 3.77 | 1.73 | 1.73 | 1.73 | 1.73 |
Shares | 46.9 | 53.2 | 59.8 | 68.8 | 104.6 | 104.6 | 104.6 | 104.6 |
Market cap | 136.5 | 172.5 | 221.6 | 259.3 | 180.8 | 180.8 | 180.8 | 180.8 |
Enterprise value | 135.1 | 169.0 | 227.5 | 265.3 | 185.0 | 216.0 | 248.6 | 278.7 |
EV/S | 33,775.4 | 42,241.4 | 56,880.5 | 66,337.2 | 46,238.7 | 54,009.8 | 62,156.9 | 80.9 |
EV/EBITDA | - | - | - | - | - | - | - | - |
EV/EBIT (adj.) | - | - | - | - | - | - | - | - |
EV/EBIT | - | - | - | - | - | - | - | - |
P/E (adj.) | - | - | - | - | - | - | - | - |
P/E | - | - | - | - | - | - | - | - |
P/B | - | 58.8 | - | - | - | - | - | - |
P/S | 34,117.3 | 43,117.9 | 55,389.8 | 64,831.5 | 45,197.6 | 45,197.6 | 45,197.6 | 52.5 |
Dividend yield | ||||||||
Equity ratio | -22.1 % | 22.3 % | -101.8 % | -148.4 % | -97.9 % | -402.0 % | -726.8 % | -1,031.1 % |
Gearing ratio | 73.9 % | -119.5 % | -52.0 % | -39.7 % | -40.7 % | -85.1 % | -91.5 % | -93.9 % |
Login required
This content is only available for logged in users
Quarter data
Q3/23 | Q4/23 | 2023 | Q1/24 | Q2/24 | Q3/24e | Q4/24e | 2024e | Q1/25e | |
---|---|---|---|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | |||||
EBITDA | -15.6 | -28.2 | -11.1 | -14.6 | -25.7 | ||||
EBIT | -15.8 | -28.6 | -11.3 | -14.8 | -26.1 | ||||
Profit before taxes | -17.2 | -30.9 | -14.4 | -15.3 | -29.7 | ||||
Net income | -17.2 | -30.9 | -14.4 | -15.3 | -29.7 |
Login required
This content is only available for logged in users
Faron Pharmaceuticals Oy: Composition of Faron Pharmaceutical's Shareholders' Nomination Board
Faron Pharmaceuticals Capital Markets Day 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits